# A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

> **NCT05253651** · PHASE3 · RECRUITING · sponsor: **Seagen, a wholly owned subsidiary of Pfizer** · enrollment: 400 (estimated)

## Conditions studied

- Colorectal Neoplasms

## Interventions

- **DRUG:** tucatinib
- **DRUG:** trastuzumab
- **DRUG:** bevacizumab
- **DRUG:** cetuximab
- **DRUG:** oxaliplatin
- **DRUG:** leucovorin
- **DRUG:** levoleucovorin
- **DRUG:** fluorouracil

## Key facts

- **NCT ID:** NCT05253651
- **Lead sponsor:** Seagen, a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-10-24
- **Primary completion:** 2026-04-03
- **Final completion:** 2029-07-27
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2026-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05253651

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05253651, "A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05253651. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*